Sexual and fertility adverse effects associated with chemotherapy treatment in women

Expert Opinion on Drug Safety

Volumn 13, Issue 6, 2014, Pages 775-783

  Turan, Volkan ^a   Oktay, Kutluk ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Fertility preservation; Infertility; Premature ovarian failure; Sexuality

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ESTROGEN; FLUOROURACIL; GONADORELIN; GONADORELIN AGONIST; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PREDNISONE; TAXANE DERIVATIVE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVOR; DISTRESS SYNDROME; FEMALE FERTILITY; FEMALE INFERTILITY; FEMALE SEXUAL DYSFUNCTION; FERTILITY PRESERVATION; HUMAN; OVARY FUNCTION; OVARY INSUFFICIENCY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE TOXICITY; REVIEW; SEXUAL FUNCTION; SEXUALITY; SOCIAL PSYCHOLOGY; SOCIAL STRESS; ANIMAL; CHEMICALLY INDUCED; FEMALE; NEOPLASMS; PREMATURE OVARIAN FAILURE; PSYCHOLOGY; PSYCHOSEXUAL DISORDER; RISK FACTOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; PRIMARY OVARIAN INSUFFICIENCY; QUALITY OF LIFE; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84901309077     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.915940     Document Type: Review

References (75)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
3. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 2012;104:386-405
4. Rodriguez-Wallberg KA, Oktay K. Fertility preservation medicine: Options for young adults and children with cancer. J Pediatr Hematol Oncol 2010;32:390-6
5. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-66
6. Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary?. Hum Reprod Update 2012;18:525-35
7. Partridge AH, Gelber S, Gelber R, et al. Delayed premature menopause following chemotherapy for early stage breast cancer: Long term results from IBSCG Trial V. Proc Am Soc Clin Oncol 2005;16s:687a
8. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1977;1:1174-6
9. González C, Boada M, Devesa M, Veiga A. Concise review: Fertility preservation: An update. Stem Cells Transl Med 2012;1:668-72
10. Oktay K, Sonmezer M. Chemotherapy and amenorrhea: Risks and treatment options. Curr Opin Obstet Gynecol 2008;20:408-15
11. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222-9 (Pubitemid 350100744
12. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-62 (Pubitemid 350070787
13. Byrne J, Fears TR, Gail MH, et al. Early menopause in long term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-93
14. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29 (Pubitemid 26134232
15. Salama M, Winkler K, Murach KF, et al. Female fertility loss and preservation: Threats and opportunities. Ann Oncol 2013;24:598-608
16. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31 (Pubitemid 46655598
17. Swain SM, Land SR, Sundry R, et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C)-docetaxol (T) arm of NSABP-30: Preliminary results. Proc Am Soc Clin Oncol 2005;16s:537a
18. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapyinduced long-Term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575-9
19. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: Double strand DNA breaks and microvascular compromise. Aging 2011;3:782-93
20. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-62 (Pubitemid 350070787
21. Titus S, Li F, Stobezki R, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 2013;5:172ra21
22. Kwee J, Schats R, McDonnell J, et al. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-43
23. van Beek RD, van den Heuvel-Eibrink MM, Laven JS. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92:3869-74 (Pubitemid 47607635
24. Giuseppe L, Attilio G, Edoardo DN, et al. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology (Am Soc Hematol Educ Program) 2007;12:141-7 (Pubitemid 46605523
25. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil Steril 2013;99:1496-502
26. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: A guideline. Fertil Steril 2013;99:37-43
27. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35 (Pubitemid 23269068
28. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. J Clin Oncol 2008;26:2630-5
29. Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole- gonadotropin protocol for fertility preservation in breast cancer patients. 2013;100:1681-5
30. Oktay K, Buyuk E, Rodriguez-Wallberg KA, Sahin G. In vitro maturation improves oocytes or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. Reprod Biomed Online 2010;20:634-8
31. Demirtas E, Elizur SE, Holzer H, et al. Immature oocytes retrieval in the luteal phase to preserve fertility in cancer patients. Reprod Biomed Online 2008;17:520-3
32. Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 2013;99:1173-81
33. Stern CJ, Gook D, Hale LG, et al. First reported clinical pregnancy following heterotopic grafting of cryopreserved ovarian tissue in a woman after a bilateral oophorectomy. Hum Reprod 2013;28:2996-9
34. Greve T, Schmidt KT, Kristensen SG, et al. Evaluation of the ovarian reserve in women transplanted with frozen and thawed ovarian cortical tissue. Fertil Steril 2012;97:1394-8
35. Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010;116:2908-14
36. Sánchez-Serrano M, Novella-Maestre E, Roselló-Sastre E, et al. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod 2009;24:2238-43
37. Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: A review of the literature. J Assist Reprod Genet 2013;30:11-24
38. Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: Clinical guidelines. Cancer Manag Res 2014;6:105-17
39. Bedoschi G, Turan V, Oktay K. Utility of GnRH-Agonists for fertility preservation in women with operable breast cancer: Is it protective?. Curr Breast Cancer Rep 2013;5:302-8
40. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-10
41. Hancke K, Strauch O, Kissel C, et al. Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo. Fertil Steril 2007;87:172-7 (Pubitemid 46013885
42. Paris F, Perez GI, Fuks Z, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002;8:901-2 (Pubitemid 35033673
43. Bonnaud S, Niaudet C, Pottier G, et al. Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 2007;67:1803-11 (Pubitemid 46389242
44. Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One 2011;6:e19475
45. Li F, Turan V, Lierman S, et al. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum Reprod 2014;29:107-13
46. Buster JE. Managing female sexual dysfunction. Fertil Steril 2013;100:905-15
47. Basson R. Female sexual dysfunction in hypopituitarism. Lancet 2007;370:737 (Pubitemid 47320791
48. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril 2013;100:916-21
49. Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: Current perspectives. Diabetes Metab Syndr Obes 2014;7:95-105
50. Kennedy SH, Rizvi S. Sexual dysfunction, depression and the impact of antidepressants. J Clin Psychopharmacol 2009;29:157-64
51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association, Washington, DC; 2013
52. Cavalheiro JA, Bittelbrunn A, Menke CH, et al. Sexual function and chemotherapy in postmenopausal women with breast cancer. BMC Womens Health 2012;12:28
53. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-Term ovarian germ cell tumor survivors: A Gynecologic Oncology Group Study. J Clin Oncol 2007;25:2792-7 (Pubitemid 47123188
54. Spencer SM, Lehman JM, Wynings C, et al. Concerns about breast cancer and relations to psychosocial well-being in a multiethnic sample of early stage patients. Health Psychol 1999;18:159-68 (Pubitemid 29152604
55. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-14 (Pubitemid 28135592
56. Eeltink CM, Incrocci L, Witte BI, et al. Fertility and sexual function in female Hodgkin lymphoma survivors of reproductive age. J Clin Nurs 2013;22(23-24):3513-21
57. Sbitti Y, Kadiri H, Essaidi I, et al. Breast cancer treatment and sexual dysfunction: Moroccan women's perception. BMC Womens Health 2011;11:29
58. Akkuzu G, Ayhan A. Sexual functions of Turkish women with gynecologic cancer during the chemotherapy process. Asian Pac J Cancer Prev 2013;14:3561-4
59. Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 2006;11:96-110 (Pubitemid 43261757
60. Kaplan HS. A neglected issue: The sexual side effects of current treatments for breast cancer. J Sex Martial Ther 1992;18:3-19
61. Schag CA, Ganz PA, Polinsky ML, et al. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 1993;11:783-93 (Pubitemid 23105689
62. Breen SJ, Baravelli CM, Schofield PE, et al. Is symptom burden a predictor of anxiety and depression in patients with cancer about to commence chemotherapy?. Med J Aust 2009;190:99-104
63. van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008;15:23-31
64. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: A survey on breast cancer survivors. Maturitas 2003;45:29-38 (Pubitemid 36712889
65. Young-McCaughan S. Sexual functioning in women with breast cancer after treatment with adjuvant therapy. Cancer Nurs 1996;19:308-19 (Pubitemid 26256098
66. Dorval M, Maunsell E, Deschenes L, et al. Long-Term quality of life after breast cancer: Comparison of 8-year survivors with population controls. J Clin Oncol 1998;16:487-94 (Pubitemid 28135590
67. Ganz PA, Desmond KA, Leedham B, et al. Quality of life in long-Term, disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst 2002;94:39-49 (Pubitemid 34082842
68. Leining MG, Gelber S, Rosenberg R, et al. Menopausal-Type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777-82 (Pubitemid 44884052
69. Schover LR. Premature ovarian failure and its consequences: Vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008;26:753-8 (Pubitemid 351264388
70. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-69
71. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63 (Pubitemid 26000605
72. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80 (Pubitemid 24030700
73. Millheiser LS, Helmer AE, Quintero RB, et al. Is infertility a risk factor for female sexual dysfunctioñ. A case control study. Fertil Steril 2010;94:2022-5
74. Akyuz A, Guvenc G, Ustunsoz A, et al. Living with gynecologic cancer: Experience of women and their partner. J Nur Scholarship 2008;40:241-7
75. Pieterse OD, Maas CP, ter Kuile MM, et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer 2006;16:1119-29 (Pubitemid 43886736 Development Development